FDA Splits Blood Irradiators into Approval Tiers
Published Date: 3/18/2026
Proposed Rule
Summary
The FDA is proposing new rules to make blood irradiators safer and more reliable. Devices that stop a serious transfusion problem will need a simpler review, while those aimed at preventing cancer spread will face a tougher approval process. If you make or use these devices, get ready to comment by May 18, 2026, and expect some extra costs for the stricter reviews.
Analyzed Economic Effects
4 provisions identified: 1 benefits, 2 costs, 1 mixed.
Metastasis Irradiators Require PMA
If you make blood irradiators intended to irradiate intraoperatively salvaged blood to prevent metastasis, the FDA proposes to classify those devices as Class III and to require filing a premarket approval (PMA) application. FDA is also issuing a proposed order requiring PMA filing for these devices, which means manufacturers must submit PMAs to seek marketing authorization.
TA-GVHD Irradiators Moved to Class II
If you make blood irradiators intended to prevent transfusion-associated graft-versus-host disease (TA-GVHD), the FDA proposes to classify those devices as Class II (special controls) and require premarket notification (510(k)). The rule would establish special controls (performance testing, labeling, and quality controls) that manufacturers must meet before marketing these prescription devices.
Option to Use Predetermined Change Plans
Manufacturers may use Predetermined Change Control Plans (PCCPs) to implement future device modifications without submitting a new 510(k) or PMA supplement if the changes are consistent with an FDA-approved or cleared PCCP. The proposal references section 515C of the FD&C Act (added by FDORA) as the legal basis for PCCPs.
Estimated Industry Costs and Benefits
FDA estimates that annualized benefits over 10 years would range from $84 to $180,268 at a 7% discount rate (primary estimate $90,176), and from $86 to $184,271 at a 3% discount rate (primary estimate $92,178). Annualized costs are estimated to range from $0.68 million to $1.51 million at 7% (primary estimate $1.07 million) and from $0.66 million to $1.53 million at 3% (primary estimate $1.07 million). The rule also identifies one-time industry costs to read the rule and revise labeling.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-05267 — Reef Fish Fishery of the Gulf of America; Shallow-Water Grouper Management Measures
The Gulf of America is planning new rules to protect shallow-water groupers like scamp and yellowmouth by lowering catch limits and setting a fixed closed season for recreational fishing. These changes affect both recreational and commercial fishers and aim to keep grouper populations healthy while more long-term plans are developed. Comments on the proposal are open until April 17, 2026, so now’s the time to speak up!
Next: 2026-05322 — Effective Date of Requirement for Premarket Approval Applications for Blood Irradiators Intended To Prevent Metastasis
The FDA is planning to require companies that make blood irradiators used during cancer surgeries to get special approval before selling them. This change helps make sure these devices are safe and effective in preventing cancer spread. If finalized, manufacturers will have about 30 months to submit their approval applications, so they should get ready soon!
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in